The BeiGene Satellite Symposium at the XIIIth International Workshop of the German CLL Study Group 2022 was chaired by Prof Barbara Eichhorst and joined by Prof Jennifer Brown. They discussed the current approaches and future direction of targeted therapy with BTK inhibitors for CLL patients.
BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.
A summary of the latest developments from 12 studies in BTK inhibition in B-cell malignancies presented at EHA2022.
The satellite symposium at EHA2022 was chaired by Paolo Ghia joined by Federico Pea, Barbara Eichhorst, Shirley D’Sa and Ramón García Sanz. They discussed next-generation BTK inhibitors in the treatment of B-cell malignancies.
Report on updates in the treatment of B-cell malignancies presented at ASH 2021.
